<DOC>
	<DOC>NCT01184599</DOC>
	<brief_summary>The purpose of this study is to evaluate the effect of aliskiren, a novel direct rennin inhibitor, on renal function and progress of renal disease in hypertensive patients with IgA nephropathy.</brief_summary>
	<brief_title>A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Glomerulonephritis</mesh_term>
	<mesh_term>Glomerulonephritis, IGA</mesh_term>
	<criteria>IgA nephropathy confirmed by renal biopsy Hypertension (&lt;= 125/75 mmHg) Patients who have been treated with angiotensin type 1 receptor blocker or angiotensinconverting enzyme inhibitor within 4 weeks Severe hypertension (&lt;= 180/110 mmHg) or secondary hypertension Patients with history of allergy or adverse effect for aliskiren Renal dysfunction (estimated Glomerular Filtration Rate &lt; 60 mL/min/1.73m2) Pregnancy Patient treated with cyclosporine Hyperkalemia (serum potassium &gt;= 5.6 mmol/L) Autoimmune disease including systemic lupus erythematosus Patients inadequate for the study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Aliskiren</keyword>
	<keyword>Albuminuria</keyword>
	<keyword>Angiotensinogen</keyword>
	<keyword>collagen type IV</keyword>
	<keyword>Transforming Growth Factor beta</keyword>
	<keyword>aldosterone</keyword>
	<keyword>renin</keyword>
	<keyword>prorenin receptor</keyword>
	<keyword>des-angiotensin I renin substrate</keyword>
	<keyword>oxidative stress</keyword>
	<keyword>advanced glycosylation end-product receptor</keyword>
	<keyword>N,N-dimethylarginine</keyword>
</DOC>